One of the major conundrums in neurological disease research is why mutations in genes that are widely expressed both inside and outside of the nervous system can lead to diseases characterized by degeneration of highly specific subpopulations of neurons. In the case of many dominant diseases, such as spinocerebellar ataxia and familial amyotrophic lateral sclerosis, it appears that neurons are selectively vulnerable to acquired protein toxicity conferred by specific amino acid changes. In contrast, recessive diseases generally result from inactivation or loss of function of a protein. In the neurological disease spinal muscular atrophy (SMA), the SMN (survival of motor neurons) gene is inactivated. The normal SMN protein is widely expressed in all tissues and is considered to be part of the so-called "housekeeping" system of the cell. It has been widely assumed that such housekeeping functions are part of basal cellular activity and therefore are unlikely to be regulated in a tissue-specific and time-dependent manner. In this issue of Cell, Zhang et al. (2008) provide some surprising new insights into the function of the SMN protein, which suggest that the general regulation of splicing through assembly of snRNPs may be more tissue specific than previously appreciated. SMA is characterized by highly selective degeneration of motor neurons, leading to weakness and wasting of muscle and can be fatal. The restriction of pathology to one specialized kind of neuron is particularly surprising given the fact that SMN is expressed in every cell in the body and its complete absence is uniformly associated with cell death (Schrank et al., 1997) . SMA is caused by mutations at the SMN locus, which result in the deletion of the SMN1 gene and variable residual copies of SMN2, a paralog that arose through an evolutionary duplication event. Due to a silent nucleotide change in exon 7 that abolishes an exonic splicing enhancer, SMN2 produces approximately 10% of the full-length functional SMN protein compared with SMN1. SMA occurs at a critical threshold level of SMN when this protein is reduced by approximately 80%. This marked decrease in SMN affects motor neurons but is sufficient to ensure the normal function of all other cells (Lefebvre et al., 1997) .
SMN and its associated protein complex is now known to have a central role in the integration of Sm core protein heptamers with snRNAs into snRNP complexes prior to importation of these complexes into the nucleus to participate in the spliceosome (Kolb et al., 2007) . Thus, reduction in SMN levels should lead to a generalized defect in splicing across a range of RNA transcripts. Could a defect in this basic function common to all cells really result in a phenotype that is specific to motor neurons? Intriguingly, the SMN protein is also present in the axonal compartment of motor neurons and other nerve cells and is localized in granules that are actively transported into neuronal processes and
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Kevin Talbot 1, * and Kay E. Davies 1, * growth cones. Here, it is associated in a protein complex with Gemin2, Gemin3, and hnRNPR, but not with spliceosomal Sm proteins, suggesting that its function in the axon may be distinct from that in the neuronal cell body (Zhang et al., 2006) . One possibility for a neuron-specific, noncanonical function for axonal SMN is that it acts as a direct chaperone of RNP-mRNA complexes, modulating local protein translation at the distal ends of motor neurons during the formation and maintenance of neuromuscular junctions in development (Figure 1 ). In their new study, Zhang and colleagues set out to understand what happens to splicing when SMN is reduced to levels approximating those seen in the tissues of SMA patients. Using a tetracycline-inducible RNAi knockdown system in cultured human cancer (HeLa) cells, SMN levels were first reduced to 20% of wild-type levels, but no effect on snRNP assembly was observed. Further reduction of SMN to 5% of wild-type levels resulted in loss of snRNP assembly and decreased cell viability. This is consistent with data from humans and mice suggesting that there is excess capacity in snRNP assembly such that a reduction in SMN does not cause a phenotype until levels fall below about 15%-20% of wild-type levels. Surprisingly, the authors observed that the reduction in snRNP assembly was associated with a differential reduction in snRNAs. In a neuronal cell line, SMN reduction by 90% similarly led to specific rather than generalized effects on snRNA levels. Notably, the U11 snRNA was specifically reduced, confirming recent studies in mice (Gabanella et al., 2007) . Furthermore, in the neuronal cell line, the profile of the differential reduction in snRNAs was different from that seen in HeLa cells.
Was this intriguing variability in the effect of SMN reduction physiologically relevant? The authors set out to investigate whether a similar consequence of SMN depletion could be observed in vivo using a mouse model of SMA, which recapitulates the main features of the human disease. As the phenotype of the SMA mice became progressively more severe, the authors observed a concordant decrease in snRNP assembly activity in the brain, spinal cord, and kidney. As with in vitro experiments in the cell lines, comparing snRNA levels between different tissues revealed striking variations regarding which snRNA classes were affected.
If the reduction in SMN and the consequent decrease in snRNP assembly have differential effects on snRNAs in different tissues, what are the downstream consequences for splicing? Using exon 
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Motor neurons are among the longest cells in the body and consequently have special mechanisms for the delivery of proteins throughout the cell through transport along axons. RNA and associated protein complexes, including SMN and some of its protein partners, are present in the axon as well as the cell body. The severe reduction in SMN protein that causes the neurological disease spinal muscular atrophy (SMA) results in a defect in SMN-mediated snRNP assembly (integration of Sm proteins in the snRNP) with alterations in the levels of specific classes of snRNAs. However, in the neuronal axon, SMN may have a function distinct from snRNP assembly, and identification of such a function may be the key to understanding the pathophysiology of SMA. Alternatively, motor neurons could be preferentially vulnerable to defects in snRNP assembly and the downstream consequences for splicing. microarrays, the investigators found remarkable tissue-specific alterations in splicing and in the production of aberrant splice products between brain, spinal cord, and kidney in SMA mice. It is not clear at what stage of disease these mice were studied, and it is possible that some of the splicing changes might be secondary to the pathological process of motor neuron degeneration itself. However, this study does provide evidence that the well-characterized function of SMN in snRNP biogenesis may not be simply a background activity common to all cells. Instead, it may be a highly regulated process that when perturbed produces distinct detrimental effects in the spinal cord, the tissue that degenerates in SMA.
It remains to be resolved why significant aberrations detected in splicing in other tissues, such as kidney, do not produce a phenotype. If aberrant splicing is a significant factor in the motor neuron degeneration seen in SMA, the challenge now is to understand precisely how this leads to cell death. This will involve a detailed assessment of the complex expression patterns of different transcripts and also a specific focus on motor neurons, as the spinal cord contains many cells not affected in SMA. Although it is clear that SMN deficiency affects motor neurons in a distinct way, there remains much to learn about the mechanistic details of cell death in this most catastrophic of neurological diseases.
Protein translocation across membrane barriers is a fundamental process in all cellular organisms and a key component to host-pathogen interactions. Multiple structural analyses and genetic and biochemical studies have led to the discovery of several protein-conducting channels that utilize a variety of mechanisms (pushing, pulling, and ratcheting) for protein translocation. In general, the posttranslational translocation of folded proteins is conducted by β-barrel channels in the bacterial outer membrane or nuclear pores comprised of α-helical transmembrane segments, whereas β-barrel channels of the mitochondrial outer membrane translocate proteins in an unfolded state. In contrast, the cotranslational translocation of bacterial and eukaryotic secretory proteins occurs across homologous α-helical channels (Sec) in the bacterial inner membrane or the endoplasmic reticulum (ER). Although many advances have been made toward understanding protein translocation across different membranes, further progress in the field is hindered by the absence of high-resolution structures that definitively portray a translocase in action.
In this issue of Cell, the elegant studies performed by Remaut et al. (2008) reveal how the large protein fibers of type 1 (Fim pathway) and P (Pap pathway) pili of pathogenic E. coli are transported across the bacterial outer membrane by a translocon termed the "usher." Using crystal structure analysis of the usher combined with single particle cryo-electron microscopy of the usher containing a translocation intermediate in lipids, the authors provide the first view of a translocase bound to a secretion intermediate at astounding resolution. The PapC usher forms a large 24 strand β-barrel channel with inner dimensions of 45 Å by 25 Å that is sufficient for the translocation of the folded pili subunits PapA/K/E/F/G or 
